Last updated on March 2019

Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

Brief description of study

This is a Phase 2, double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety and maintenance of efficacy of an optimized once-daily (qd) dose of NBI-98854 in pediatric subjects with TS.

Clinical Study Identifier: NCT03530293

Contact Investigators or Research Sites near you

Start Over

Neurocrine Clinical Site

Ann Arbor, MI United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.